☰

Christina L. Kline, Ph.D. - Publications

Affiliations: 
2011 Pennsylvania State University, State College, PA, United States 
Area:
Molecular Biology, Biochemistry, Oncology
Tree Info Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Wagner J, Kline CL, Zhou L, Campbell KS, MacFarlane AW, Olszanski AJ, Cai KQ, Hensley HH, Ross EA, Ralff MD, Zloza A, Chesson CB, Newman JH, Kaufman H, Bertino JR, et al. Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment. The Journal of Clinical Investigation. PMID 29533922 DOI: 10.1172/Jci96711  0.459
2017 Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogues of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle (Georgetown, Tex.). 0. PMID 28489985 DOI: 10.1080/15384101.2017.1325046  0.564
2016 Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, et al. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. PMID 27602582 DOI: 10.18632/Oncotarget.11814  0.342
2016 Kline CL, Van den Heuvel AP, Allen JE, Prabhu VV, Dicker DT, El-Deiry WS. ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases. Science Signaling. 9: ra18. PMID 26884600 DOI: 10.1126/Scisignal.Aac4374  0.447
2016 Prabhu VV, Lulla A, Kline CL, Van den Heuvel PJ, Talekar MK, Wagner JM, Tarapore RS, Dicker DT, Garnett MJ, McDermott U, Benes CH, Pu JJ, Claxton DF, Oster W, Allen JE, et al. Single Agent and Combinatorial Efficacy of First-in-Class Small Molecule ONC201 in Acute Leukemia and Multiple Myeloma Blood. 128: 2759-2759. DOI: 10.1182/Blood.V128.22.2759.2759  0.515
2015 Zhang S, Zhou L, Hong B, van den Heuvel AP, Prabhu VV, Warfel NA, Kline CL, Dicker DT, Kopelovich L, El-Deiry WS. Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53. Cancer Research. 75: 3842-52. PMID 26294215 DOI: 10.1158/0008-5472.Can-13-1079  0.349
2015 Kline CL, Heuvel Pvd, Allen JE, Dicker DT, El-Deiry WS. Abstract 674: Early integrated stress response induction of ATF4 is required for the anticancer effects of the dual Akt/ERK inhibitor and TRAIL pathway inducer ONC201/TIC10 Cancer Research. 75: 674-674. DOI: 10.1158/1538-7445.Am2015-674  0.531
2015 Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. Abstract 4499: Cytotoxicity, biochemical activity, and structural analysis of ONC201 and comparisons to a biologically inactive isomer Cancer Research. 75: 4499-4499. DOI: 10.1158/1538-7445.Am2015-4499  0.396
2015 Kline CL, Lulla AR, Dicker D, Allen JE, El-Deiry W. Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis Cancer Research. 75: 2942-2942. DOI: 10.1158/1538-7445.Am2015-2942  0.485
2014 Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 5: 12728-37. PMID 25587031 DOI: 10.18632/Oncotarget.2890  0.365
2014 Prabhu VV, Lulla AR, Wagner JM, Hernandez-Borrero LJ, Talekar MK, Kline CL, Dicker DT, Barth BM, Pu JJ, Claxton DF, Allen JE, El-Deiry WS. Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins Blood. 124: 5237-5237. DOI: 10.1182/Blood.V124.21.5237.5237  0.523
2013 Irby RB, Kline CL. Par-4 as a potential target for cancer therapy. Expert Opinion On Therapeutic Targets. 17: 77-87. PMID 23062118 DOI: 10.1517/14728222.2013.731047  0.683
2011 Kline CL, Sheikh HS, Scicchitano A, Gingrich R, Beachler C, Finnberg NK, Liao J, Sivik J, El-Deiry WS. Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients. Cancer Biology & Therapy. 12: 557-68. PMID 21931273 DOI: 10.4161/Cbt.12.7.18059  0.326
2011 Kline CL, Irby RB. The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU. Apoptosis : An International Journal On Programmed Cell Death. 16: 1285-94. PMID 21910008 DOI: 10.1007/S10495-011-0648-3  0.712
2011 Sharma AK, Kline CL, Berg A, Amin S, Irby RB. The Akt inhibitor ISC-4 activates prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 4474-83. PMID 21555373 DOI: 10.1158/1078-0432.Ccr-10-2370  0.719
2010 Wang BD, Kline CL, Pastor DM, Olson TL, Frank B, Luu T, Sharma AK, Robertson G, Weirauch MT, Patierno SR, Stuart JM, Irby RB, Lee NH. Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NF kappaB and microRNA network. Molecular Cancer. 9: 98. PMID 20433755 DOI: 10.1186/1476-4598-9-98  0.68
2010 Pastor DM, Poritz LS, Olson TL, Kline CL, Harris LR, Koltun WA, Chinchilli VM, Irby RB. Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines. International Journal of Clinical and Experimental Medicine. 3: 69-83. PMID 20369042  0.689
2010 Irby RB, Kline CL, Sharma AK. Abstract 1209: Par-4 as therapy for colon cancer Cancer Research. 70: 1209-1209. DOI: 10.1158/1538-7445.Am10-1209  0.738
2009 Kline CL, Shanmugavelandy SS, Kester M, Irby RB. Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU. Cancer Biology & Therapy. 8: 1831-7. PMID 19729995 DOI: 10.4161/Cbt.8.19.9592  0.752
2009 Kline CL, Olson TL, Irby RB. Src activity alters alpha3 integrin expression in colon tumor cells. Clinical & Experimental Metastasis. 26: 77-87. PMID 18839319 DOI: 10.1007/S10585-008-9215-X  0.664
2008 Kline CL, Jackson R, Engelman R, Pledger WJ, Yeatman TJ, Irby RB. Src kinase induces tumor formation in the c-SRC C57BL/6 mouse. International Journal of Cancer. Journal International Du Cancer. 122: 2665-73. PMID 18351644 DOI: 10.1002/Ijc.23445  0.695
Show low-probability matches.